Johnson & Johnson

AUSTIN, Texas and TOKYO, Dec. 17, 2025 /PRNewswire/ -- According to DataM Intelligence, the global Disease-Modifying Therapies (DMTs) Market was valued at USD 65.32 billion in 2024 and is projected to reach USD 112.64 billion by 2033, expanding at a CAGR of 6.2% during the forecast period 2025–2033. This steady yet structurally important growth reflects a fundamental transformation in chronic disease management. Healthcare systems are increasingly shifting from symptom-focused treatment toward therapies that alter disease progression, reduce irreversible tissue damage, and improve long-term functional outcomes. By 2031, disease-modifying therapies will be firmly positioned as cornerstone treatments across autoimmune, inflammatory, and neurodegenerative disorders, driven by sustained biologics innovation, expanding oral small-molecule pipelines, and earlier diagnosis enabled by precision medicine. Request Executive Sample | Disease-Modifying Therapies (DMT) Market Intelligence: Why Disease-Modifying Therapies Are Central to the Future of Chronic Care The strategic importance of DMTs is rooted in three converging realities reshaping global healthcare. The burden of chronic immune-mediated diseases is rising sharply. Conditions such as multiple sclerosis, rheumatoid arthritis, lupus, and Crohn's disease are increasing in prevalence due to aging populations, lifestyle changes, and improved diagnostic capability. These diseases impose long-term disability and escalating healthcare costs when not effectively controlled early. Clinical expectations have shifted. Patients, providers, and payers increasingly prioritize durable remission, delayed disease progression, and preserved quality of life over short-term symptom relief. Disease-modifying therapies directly address these goals by targeting the underlying biological drivers of disease. Biologic science and targeted small molecules have matured. Advances in immunology, monoclonal antibody engineering, and intracellular pathway modulation have expanded the therapeutic arsenal, enabling more precise and personalized interventions. Together, these factors are driving sustained investment and adoption of disease-modifying therapies across global healthcare systems. Market Segmentation Analysis By Drug Class Biologics dominate the disease-modifying therapies market, accounting for approximately 68% of global revenue in 2024, equivalent to nearly USD 44.4 billion. Monoclonal antibodies and advanced biologic constructs offer high specificity, strong efficacy, and durable disease control, particularly in autoimmune and inflammatory conditions. Their dominance is reinforced by long treatment durations and premium pricing in developed markets. Small-molecule drugs represent the remaining 32%, or approximately USD 20.9 billion. This segment is gaining strategic importance due to oral administration, lower manufacturing complexity, and growing innovation in kinase inhibitors and immune-modulating pathways. According to DataM Intelligence Analysis, ' Small molecules will register faster relative growth through 2033, supported by patient preference for oral therapies and expanding pipeline approvals'. By Disease Indication Multiple sclerosis (MS) remains the single largest indication, accounting for approximately 34% of market value, or about USD 22.2 billion in 2024. DMTs have fundamentally reshaped MS treatment by reducing relapse rates, slowing disability progression, and extending functional independence, making early and continuous therapy standard clinical practice. Rheumatoid arthritis (RA) represents around 27% of the market, equivalent to USD 17.6 billion. Despite market maturity, RA continues to drive revenue through biologic switching, combination therapy strategies, and use of DMTs earlier in the disease course. Crohn's disease contributes approximately 14%, or USD 9.1 billion, reflecting rising incidence and long-term treatment requirements. Lupus accounts for roughly 9%, or USD 5.9 billion, with increasing biologic penetration addressing historically unmet needs. Other indications, including psoriasis, ankylosing spondylitis, and emerging immune-mediated conditions, make up the remaining 16% and represent an important pipeline-driven growth opportunity. According to DataM Intelligence Analysis, 'Multiple sclerosis and rheumatoid arthritis will remain the primary revenue anchors, while Crohn's disease and lupus will deliver incremental growth as novel mechanisms enter clinical practice'. By Route of Administration Parenteral therapies accounted for approximately 61% of market revenue in 2024, or about USD 39.8 billion. Injectable and infusion-based biologics continue to dominate due to their efficacy, established clinical use, and suitability for complex immune modulation. Oral therapies represented 39%, or around USD 25.5 billion. Oral disease-modifying drugs are gaining traction due to patient convenience, improved adherence, and expanding small-molecule innovation. According to DataM Intelligence analysis, ' Oral therapies will steadily increase their share through 2033, particularly in early-stage disease management'. By Distribution Channel Hospital pharmacies remain the primary distribution channel, accounting for approximately 54% of total market value, or USD 35.3 billion. This reflects the clinical complexity of DMTs, the need for specialist oversight, and the prevalence of infusion-based biologics. Retail pharmacies account for the remaining 46%, or USD 30.0 billion, driven by growth in oral therapies and decentralized care models. Request Customized Intelligence Aligned to Your Business Strategy: Regional Performance United States The United States represents the largest disease-modifying therapies market globally, accounting for an estimated 42% of total revenue, equivalent to USD 27.4 billion in 2024. Key Growth Drivers: High prevalence of autoimmune diseases Strong biologics reimbursement frameworks Early adoption of innovative therapies Robust clinical trial infrastructure By 2033, the U.S. market alone is projected to exceed USD 47 billion, reinforcing its central role in global DMT innovation and commercialization. Europe Europe accounts for approximately 30% of global market value, supported by strong specialist care networks and increasing use of biosimilars to expand access while managing costs. Asia-Pacific Asia-Pacific represents a rapidly expanding opportunity, driven by improving diagnosis rates, healthcare infrastructure investment, and rising awareness of disease-modifying treatment benefits, particularly in Japan, China, and South Korea. Competitive Landscape - Strategic Players Shaping the Market The disease-modifying therapies market is characterized by strong intellectual property portfolios, long product lifecycles, and deep R&D investment. Genentech USA, Inc. continues to lead biologic innovation across autoimmune and inflammatory diseases, supported by parent-company annual revenues exceeding USD 60 billion and sustained immunology R&D investment. Novartis AG maintains a strong DMT portfolio with global pharmaceutical revenues of over USD 45 billion, emphasizing oral small-molecule innovation alongside biologics. Johnson & Johnson and AbbVie Inc. leverage diversified immunology franchises, with AbbVie alone generating over USD 55 billion in annual revenue, a significant portion driven by disease-modifying therapies. AstraZeneca and GSK are expanding immune-modulation pipelines, integrating biologics and precision medicine strategies. Amgen Inc. and UCB, Inc. continue to strengthen their presence through biologics development and lifecycle management. Takeda Pharmaceuticals maintains strategic focus on immune-mediated and gastrointestinal disorders, supported by global revenues exceeding USD 30 billion. What Will Define the Market By 2031–2033 By 2031, the disease-modifying therapies market will approach USD 105 billion, driven by: Earlier initiation of DMTs following diagnosis Expansion into additional immune-mediated indications Continued biologics innovation Increased penetration of oral disease-modifying drugs According to DataM Intelligence Analysis: Biologics will remain the dominant revenue segment Multiple sclerosis will continue as the largest indication Oral therapies will gain steady share The U.S. will maintain its position as the single largest market By 2033, disease-modifying therapies will be firmly embedded in standard-of-care treatment algorithms, shifting healthcare systems toward long-term disease control rather than episodic intervention. Purchase Corporate License | Disease-Modifying Therapies Market Intelligence: Executive Takeaway For pharmaceutical leaders and healthcare decision-makers, disease-modifying therapies represent one of the most durable and strategically important segments in modern medicine. Organizations that succeed will be those that: Invest in differentiated mechanisms of action Expand access while managing cost pressures Align clinical value with long-term outcomes Anticipate shifts toward oral and personalized therapies As chronic diseases continue to reshape global healthcare demand, disease-modifying therapies will remain central to improving outcomes, controlling costs, and redefining patient care over the next decade. Related Report: Crohn's Disease Market Gains Strategic Momentum as Pharma Companies Advance Biologics and Targeted Therapies. Rheumatoid Arthritis Drugs Market Enters Next Innovation Cycle as Biologics and Targeted Therapies Redefine Treatment Strategies. Multiple Sclerosis Therapeutics Market Enters Next Growth Phase as Pipeline Innovation and Targeted Therapies Reshape Treatment Strategies. Lupus Therapeutics Market Enters a New Growth Phase as Targeted Biologics and Pipeline Innovation Address High Unmet Need. Biologics Market Enters Next Expansion Phase as Advanced Therapies and Pipeline Innovation Reshape Global Pharma Portfolios. About DataM Intelligence DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations. To find out more, visit or follow us on Twitter, LinkedIn, and Facebook. Contact: Sai Kiran DataM Intelligence 4market Research LLP Ground floor, DSL Abacus IT Park, Industrial Development Area Uppal, Hyderabad, Telangana 500039 USA: +1 877-441-4866 Email: [email protected] Logo: SOURCE DataM Intelligence 4 Market Research LLP 21% more press release views with Request a Demo

iStock, RomoloTavani These deals radically reshaped the biopharma world, either by one vaccine rival absorbing another, a Big Pharma doubling down after another failed acquisition or, in the case of Pfizer and Novo, two heavyweights duking it out over a hot obesity biotech. 2025 proved to be a high-drama year for dealmaking as pharmas fought over companies, swallowed their rivals and found inspiration in other companies’ transactions. The biggest deal of the year—Johnson & Johnson’s $14.6 billion buy of Intra-Cellular all the way back in January—didn’t even make the list of what BioSpace editors consider the most influential M&A deals of the year. While the year won’t go down as the biggest in value by any means, some of these deals will have an indelible impact on the industry for years to come. Pharmas dealt in obesity, cancer, cell therapy, mental health and a slate of others, growing and expanding their businesses. These deals, such as Pfizer’s fight to get an up-and-coming obesity biotech, AbbVie doubling down on psychedelics for mental health conditions and the fall of gene therapy’s darling shook and reshaped the biopharma sector in 2025, setting up excitement for the year ahead. Read on for 2025’s seven most impactful biopharma M&A deals. 1. The Pfizer/Novo/Metsera Saga, Obviously There could only be one story in the top spot, and it was the epic bidding war between Pfizer and Novo Nordisk over obesity startup Metsera. To make a long story short: Pfizer tried and repeatedly failed to develop a competitive obesity pipeline in-house. After several flunks earlier in 2025, the company looked to its business development team. Pfizer made a $4.9 billion offer for Metsera in September, to gain access to a long-acting GLP-1 and a long-acting amylin analogue. The deal seemed to be on the way to closing, until Novo offered an unsolicited $8.5 billion bid for the company a month later. Facing a different set of problems as the obesity space’s early leader, Novo was looking to rebuild its pipeline as rival Eli Lilly seemingly scored one win after another. A series of counteroffers, legal threats and FTC scrutiny followed, with Pfizer finally winning out for a price of about $9.2 billion for Metsera. With the dust now settled, Pfizer is back in the obesity business. The size of the obesity market, according to a Reports and Data analysis, is set to hit $27 billion yearly by as soon as 2028 and $150 billion by the early 2030s. The fight over Metsera seemed to indicate that Big Pharmas are still willing to go big in the obesity market. On the other hand, analysts wondered: Was it worth it? Obesity Is Metsera Worth the Fuss? Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: Is the obesity biotech really worth this much effort? November 5, 2025 · 4 min read · Annalee Armstrong 2. BMS Spends $1.5B for Orbital as Others Retreat From Cell Therapy Over the course of 2025, there was a massive pullback from cell therapy, with Takeda and Novo Nordisk abandoning billions in long-term investments. But Bristol Myers Squibb doubled down. The Big Pharma plunked down $1.5 billion to get Orbital Therapeutics, snagging OTX-201, a circular RNA therapy that induces a patient’s own cells to make anti-CD19 CAR type constructs. The therapy is being tested to treat B cell–driven autoimmune disorders. The Orbital deal deepens BMS’ roots in cell therapy, adding to its approved anti-BCMA therpay Abecma , for relapsed or refractory multiple myeloma, and the CD19-directed Breyanzi for blood cancers. But the buy also told the industry that there is still potential in cell therapy if you know where to look. 3. Novo Deepens MASH Stature With $5.2B Akero Buy Metabolic dysfunction–associated steatohepatitis—MASH—is suddenly one of the buzziest sectors in the pharma industry again. Novo Nordisk paid $5.2 billion to get Akero Therapeutics in October, adding efruxifermin, which reduced liver fibrosis by 24% in a Phase IIb study that read out earlier this year . It was such a good result that it pushed Roche to go hunting for an anti-MASH molecule, spurring that company’s purchase of 89bio for $3.5 billion in September. The Akero buy only deepened Novo Nordisk’s presence in the MASH space, as its multi-blockbuster GLP-1 Wegovy received approval for the liver condition in August . The Roche and Novo deals marked a turning point for the MASH space, which Big Pharma had largely abandoned years ago after numerous failures. The small biopharma Madrigal Pharmaceuticals finally broke through with the 2024 approval of Rezdiffra in MASH, reigniting interest in the space. Psychedelics Psychedelics Space Enters New Era as AbbVie Dives In With AbbVie’s $1.2 billion acquisition of Gilgamesh Pharmaceuticals’ lead depression drug, the psychedelic therapeutics space has soundly rebounded from Lykos’ rejection last year. There are now seven programs in Phase III trials across the sector, with multiple companies vying for that first approval. September 22, 2025 · 6 min read · Heather McKenzie 4. AbbVie Goes Back to the Mental Health Well With Gilgamesh Buy AbbVie paid $1.2 billion to get just one asset from neurotech biotech Gilgamesh Pharmaceuticals in August . That gave them an entree at a table that Big Pharma has nibble at for a while: psychedelics. AbbVie gained bretisilocin, a fast-acting analogue of dimethyltryptamine (DMT) for major depressive disorder (MDD). The rest of Gilgamesh’s pipeline spun out into a separate company, Gilgamesh Pharma Inc., which carries on an existing AbbVie partnership. The Gilgamesh buy suggested that AbbVie was undeterred after a $9 billion quagmire in the form of Cerevel . AbbVie paid the princely sum to get the company and its schizophrenia asset emraclidine in 2023, which went on to flunk Phase II trials one year later . The Gilgamesh deal helped galvanize interest in psychedelics. AbbVie’s investment came at a time when most neuropsych-focused pharmas “have kept a distance,” from psychedelics according to Aaron Bartlone, CEO of the Canadian mental health biotech Cybin. The only other Big Pharmas in the psychedelics space right now are Johnson & Johnson, with its ketamine derivative Spravato, and Japanese giant Otsuka. The latter paid $59 million in 2023 to absorb Mindset, a Canadian psychedelics biotech. 5. Bluebird—Ahem, Genetix—Goes Private Bluebird was the standard bearer of gene therapy, until it wasn’t. Private equity outfits The Carlyle Group and SK Capital bought the biotech, which at one time had been worth north of $10 billion, for a scant $50 million in February . It was a precipitous fall for bluebird, which had more than $1 billion in cash the first quarter of 2021. That number fell to just $118.7 million by the third quarter of 2023 . Gene therapy is facing a “ cold winter ,” as promising science has not translated to good business, with sky-high costs and infrastructure issues hobbling the sector. Still, Carlyle and SK have options for turning bluebird’s assets into profits—including just selling the three approved gene therapies off, as PitchBook Senior Biotech Analyst Kazi Helal suggested to BioSpace in July. Those assets are Lyfgenia for sickle cell disease, Skysona for cerebral adrenoleukodystrophy and Zynteglo for beta thalassemia. Bluebird’s sale was the biggest indicator of a growing trend: the entry of private equity into the biotechnology space. In the last few years, PE firms like BlackStone have launched life sciences–focused funds, put billions of dollars into backing new ventures and even funded individual professors’ research. Bluebird renamed itself to Genetix in September , shedding a unique biopharma name adopted in 2010 and returning to its original moniker. Deals Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’ Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called bluebird bio? We wanted to know. July 2, 2025 · 7 min read · Annalee Armstrong 6. Once Hot Sage Fades Away in Supernus Buy In late November 2024, Sage’s lead asset dalzanemdor flunked a Phase II trial for Huntington’s disease, the third such fail for the drug. It was just the capstone of a series of setbacks for Sage over the last few years; another asset, SAGE-324, flunked a Phase II study for essential tremor and was discontinued, and its Biogen-partnered postpartum depression drug Zurzuvae failed to get FDA approval in major depressive disorder. Maryland-based Supernus stepped in and scooped up Sage for $795 million in June . It was a “good end” for the company, according to analysts, and represented a much larger buyout than one put forward by long-time partner Biogen in January. Biogen offered $469 million to fold in its partner in Zurzuvae in January 2025 . Sage declined the offer with extreme prejudice, going so far as to sue Biogen. Along with Zurzuvae, Supernus absorbed Sage’s other approved drugs: the ADHD medication Qelbree; Onapgo, a wearable device for treating motor fluctuations associated with Parkinson’s disease; and Gocovri, for treating dyskinesia in Parkinson’s. Stifel analysts, writing at the time of the Supernus buy, said that it “feels like an unremarkable outcome for a company that was once one of the hottest stories” in treating central nervous system disorders. 7. BioNTech Ends CureVac Rivalry With a Pot of Money In 2022, BioNTech said in a lawsuit that it faced “threats of a groundless patent infringement suit” from a company that was “unable to bring to market any product to help in the fight against COVID-19.” Three years later, BioNTech bought that company, CureVac, for $1.25 billion, ending a winding legal drama that was still ongoing at the time of the deal. That purchase gave BioNTech a new mRNA-based therapy for the tough brain cancer glioblastoma. Despite both companies gaining fame for working on vaccines, the deal was motivated mostly by interest in cancer. Getting access to CureVac’s pipeline of cancer immunotherapies “marks the next milestone in the execution of [BioNTech’s] oncology strategy,” the company said in announcing the deal. Despite regulatory headwinds prevailing against mRNA-based therapies and vaccines in the U.S.—like the federal government canceling hundreds of millions of dollars in research dollars aimed at projects using the technology—BioNTech’s bid to swallow up its rival is a signal that, even as the company diversifies into other modalities like bispecifics , mRNA-based therapies as a platform are here to stay. .responsive-container { display: flex; flex-wrap: wrap; border: 1px solid #ededed; font-family: Helvetica, Arial, Sans-Serif; padding: 20px 20px 10px 20px; } .column-left { flex: 1; max-width: 45%; padding: 20px 20px 10px 20px; } .column-right { flex: 2; padding: 20px 20px 10px 20px; } @media (max-width: 768px) { .column-left, .column-right { max-width: 100%; flex: 100%; padding: 10px 0; } } Subscribe to BioPharm Executive! Market insights, trending business and policy stories for biopharma leaders hbspt.forms.create({ region: "na1", portalId: "4413123", formId: "7c139b3c-ff0b-44e0-bffe-f449801dca59", onFormSubmitted: function($form, data) { window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'GTMevent', 'event_name': 'newsletter_sign_up' }); } });

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal FDA safety review finds no confirmed pediatric deaths caused by COVID-19 vaccines, and Commissioner Marty Makary says no black box warning will be attached to the shots; and BioSpace looks at six biotechs that could be pharma’s next buy. > Listen on Spotify > Listen on Apple Products > Listen on Amazon Music > Listen on iHeart Eli Lilly is wrapping up 2025 with record-breaking weight loss in a late-stage trial for its triple hormone receptor agonist retatrutide . Results from the Phase III TRIUMPH-4 trial exceeded analyst expectations, leading BMO Capital markets to cleverly dub it “a true TRIUMPH.” Also in the weight loss arena, Zealand Pharma inked a deal with China’s OTR Therapeutics worth up to $2.5 billion to collaborate on next-gen drugs for obesity and other metabolic diseases, and Rhythm Pharmaceuticals awaits a Dec. 20 FDA verdict for Imcivree in hypothalamic obesity. Turning to the FDA, reports broke late last week that the agency was considering slapping a black box label—its strictest warning—on COVID-19 vaccines. Commissioner Marty Makary denied those reports on Monday, stating on Bloomberg TV that the FDA has “no plans” to make such a move. This follows an internal memo from Vinay Prasad leaked over Thanksgiving in which the CBER director claimed that “at least” 10 children have died “because of” COVID-19 vaccines. An internal safety review published last week refuted this conclusion, instead concluding that between zero and seven deaths could be linked to the shots. Pfizer CEO Albert Bourla , for one, is tired of the recent rhetoric from HHS on vaccines and hopes they are “an anomaly” that will be corrected soon. With strong words about the administration’s sentiment on vaccines, Bourla prominsed Pfizer’s continued investment in vaccines despite declining revenue. Pfizer this week lowered its 2026 guidance to $62.5 billion in revenue, missing analyst consensus. Clinical research 5 of 2025’s Defining Clinical Wins In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal parts. Here are some of this year’s most glorious clinical trial victories. December 15, 2025 · 9 min read · Tristan Manalac The FDA has also granted several approvals in the past week, to Amgen , Milestone Pharmaceuticals and AstraZeneca and Daiichi Sankyo . USAntibiotics also snagged a greenlight, for Augmentin XR , the first approval to be given under the agency’s new Commissioner’s National Priority Voucher (CNPV) program. Also this week, Johnson & Johnson scored a CNPV ticket—without even having to apply—for its investigational combo of Tecvayli plus Darzalex for relapsed or refractory multiple myeloma after the FDA was impressed by Phase III data. In ClinicaSpace this week, we highlighted 5 of 2025’s Defining Clinical Wins and The 5 Most Painful Clinical Trial Failures of 2025 . This past week provided a few more on each front. In the winner’s circle, Immunome’s desmoid tumor drug and and Kyverna’s CAR T for stiff person syndrome both aced pivotal trials, while Sanofi’s MS drug tolebrutinib and Gilead and Arcus’ TIGIT therapy domvanalimab each failed Phase III tests. And in BioPharm Executive, we highlight 6 Biotechs That Could Be Big Pharma’s Next M&A Target , and more M&A predictions for 2026.